FDA Drug Safety Surveillance: Beyond Daily Adverse Event Data
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events - including heart attack, stroke, and cardiovascular death - in individuals with...
- The SELECT trial followed participants for an average of 3.4 years.
- These findings primarily affect individuals with obesity *and* pre-existing cardiovascular disease.
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events – including heart attack, stroke, and cardiovascular death – in individuals with obesity and established cardiovascular disease who where treated with semaglutide (Ozempic) compared to those receiving a placebo. The study, involving over 17,600 participants, initially aimed to determine if semaglutide could reduce the risk of these events, but the results showed a statistically meaningful, though modest, increase in risk within the treatment group. This finding challenges previous assumptions about the cardiovascular safety of GLP-1 receptor agonists like semaglutide.
Key Findings and Data
The SELECT trial followed participants for an average of 3.4 years. The primary composite outcome of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death occurred in 6.5% of those receiving semaglutide versus 5.8% of those receiving placebo. This translates to a hazard ratio of 1.13, indicating a 13% increased risk. Importantly,the trial population consisted of adults with a body mass index (BMI) of 27 or higher and established cardiovascular disease,such as prior heart attack or stroke.The study did *not* include individuals with type 2 diabetes, focusing solely on those with obesity and cardiovascular risk.
| Outcome | Semaglutide (6.5%) | Placebo (5.8%) | Hazard Ratio |
|---|---|---|---|
| MACE (Myocardial Infarction, Stroke, or CV Death) | 6.5% | 5.8% | 1.13 |
| Hospitalization for Heart Failure | 2.6% | 2.3% | 1.13 |
Who is Affected? Understanding the Implications
These findings primarily affect individuals with obesity *and* pre-existing cardiovascular disease. It does *not* necessarily mean that semaglutide is unsafe for everyone. Patients currently taking semaglutide for weight loss or diabetes management,especially those without a history of heart problems,should not panic,but should discuss these results with their healthcare provider. The results highlight the importance of careful patient selection and risk assessment before initiating semaglutide therapy. Individuals with multiple cardiovascular risk factors may require more intensive monitoring while on the medication.
What Does This Mean? Expert Analysis
Timeline of Events
- November 2023: Results of the SELECT trial are presented at the American Heart Association Scientific Sessions.
- Ongoing: Further analysis of the SELECT trial data is underway to explore potential subgroups and mechanisms.
- Future: Regulatory agencies (FDA, EMA) are expected to review